Felodipine transdermal device and methods

Details Felodipine transdermal device and methods Felodipine transdermal device and methods

2006-03-28

2006-03-28

Page, Thurman K. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

C424S448000

Reexamination Certificate

active

07018649

ABSTRACT:
A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.

REFERENCES:
patent: 5045319 (1991-09-01), Chien et al.
patent: 5091186 (1992-02-01), Miranda et al.
patent: 5225199 (1993-07-01), Hidaka et al.
patent: 5240711 (1993-08-01), Hille et al.
patent: 5834496 (1998-11-01), Young
patent: 5879701 (1999-03-01), Audett et al.
patent: 5968547 (1999-10-01), Reder et al.
patent: 6103735 (2000-08-01), Aslanian et al.
patent: 6541479 (2003-04-01), Mehanna et al.
patent: 2003/0199492 (2003-10-01), Scott
patent: 9310781 (1993-06-01), None
patent: 9619975 (1995-12-01), None
patent: 9637231 (1996-11-01), None
patent: 9836728 (1998-08-01), None
patent: 0045797 (2000-08-01), None
Diez, I., et al., “Influence of d-limonene on the Transdermat Oenetration of Felodipine”, European J. of Metab and Pharm., 1998 vol. 23 (1) pp 7-12.

Affiliated with

Also associated with

Rating

Felodipine transdermal device and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Felodipine transdermal device and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Felodipine transdermal device and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3553966